Breaking News

Mayne Pharma Appoints Blake Cullen VP of Business Development for US Generics

June 16, 2014

Mayne Pharma has apointed Blake Cullen VP of Business Development for its U.S. generic products division.  Mr. Cullen brings over 15 years of industry experience to the position, in the areas of strategic planning, mergers and acquisitions, product in-licensing and out-licensing for companies such as Rhodes Pharma, Libertas Pharma, Paddock Labs and Prasco labs.  With a J.D. degree and an MBA from the University of Cincinnati and a B.S. from Seton Hall, Mr. Cullen has also served as general counsel at Qualitest Pharmaceuticals.  Mayne's generics business, established less than 10 years ago, currently markets more than 20 products and is developing 25 new products, with 13 ANDAs filed with FDA.  Expanding this portfolio will come through both organic development and bolt on acquisitions, said Stefan Cross, Mayne Pharma's president. "Blake brings a strong track record of building pharmaceutical product lines and corporate value," Cross said. 

blog comments powered by Disqus
  • Solid Dosage Manufacturing Trends

    Solid Dosage Manufacturing Trends

    Tim Wright, Editor||March 6, 2015
    Big Pharma continues to unload in-house manufacturing, partnering with contract service providers that can meet their cGMP needs.

  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 21, 2014
    Big Pharma continues to face the impact of competitive pressures, fluctuating currencies, the patent cliff, and pipeline surprises, all of which were reflected in financial results last year.

  • Newsmakers: Nancy Lurker

    Newsmakers: Nancy Lurker

    Gil Roth, Editor||March 7, 2014
    A CSO adapts for a new era in healthcare.